Amygdala Nuclei Atrophy in Cognitive Impairment and Dementia: Insights from High-Resolution Magnetic Resonance Imaging

<i>Background and Objectives:</i> Cognitive impairment affects memory, reasoning, and problem-solving, with early detection being critical for effective management. The amygdala, a key structure in emotional processing and memory, may play a pivotal role in detecting cognitive decline. T...

Full description

Saved in:
Bibliographic Details
Main Authors: Evija Peiseniece, Nauris Zdanovskis, Kristīne Šneidere, Andrejs Kostiks, Guntis Karelis, Ardis Platkājis, Ainārs Stepens
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/1/130
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<i>Background and Objectives:</i> Cognitive impairment affects memory, reasoning, and problem-solving, with early detection being critical for effective management. The amygdala, a key structure in emotional processing and memory, may play a pivotal role in detecting cognitive decline. This study examines differences in amygdala nuclei volumes in patients with varying levels of cognitive performance to evaluate its potential as a biomarker. <i>Material and methods:</i> This cross-sectional study of 35 participants was conducted and classified into three groups: the normal (≥26), moderate (15–25), and low (≤14) cognitive performance groups based on the Montreal Cognitive Assessment (MoCA) scores. High-resolution magnetic resonance imaging at 3.0 T scanner was used to assess amygdala nuclei volumes. <i>Results:</i> Significant amygdala atrophy was observed in multiple amygdala nuclei across cognitive performance groups, with more pronounced changes in the low-performance group. The right hemisphere nuclei, including the lateral and basal nuclei, showed more significant differences, indicating their sensitivity to cognitive decline. <i>Conclusions:</i> This study highlights the potential of amygdala nuclei atrophy as a biomarker for cognitive impairment. Additional research with larger sample sizes and longitudinal designs is needed to confirm these findings and determine their diagnostic value.
ISSN:1010-660X
1648-9144